Compare ALEMBIC PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STRIDES PHARMA SCIENCE ALEMBIC PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 16.0 45.2 35.4% View Chart
P/BV x 6.4 2.1 301.3% View Chart
Dividend Yield % 0.6 0.2 260.4%  

Financials

 ALEMBIC PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6641,147 57.9%   
Low Rs412642 64.2%   
Sales per share (Unadj.) Rs208.7317.2 65.8%  
Earnings per share (Unadj.) Rs31.07.8 395.1%  
Cash flow per share (Unadj.) Rs37.125.1 148.1%  
Dividends per share (Unadj.) Rs5.502.00 275.0%  
Dividend yield (eoy) %1.00.2 457.1%  
Book value per share (Unadj.) Rs144.2274.3 52.6%  
Shares outstanding (eoy) m188.5289.50 210.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.8 91.5%   
Avg P/E ratio x17.4114.0 15.2%  
P/CF ratio (eoy) x14.535.7 40.6%  
Price / Book Value ratio x3.73.3 114.4%  
Dividend payout %17.725.5 69.6%   
Avg Mkt Cap Rs m101,46180,058 126.7%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m7,4674,341 172.0%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m39,34728,394 138.6%  
Other income Rs m94941 10.0%   
Total revenues Rs m39,44129,334 134.5%   
Gross profit Rs m8,7363,965 220.3%  
Depreciation Rs m1,1521,540 74.8%   
Interest Rs m1841,962 9.4%   
Profit before tax Rs m7,4931,403 534.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-93-168 55.2%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,56897 1,611.0%   
Profit after tax Rs m5,844702 832.3%  
Gross profit margin %22.214.0 159.0%  
Effective tax rate %20.96.9 301.7%   
Net profit margin %14.92.5 600.6%  
BALANCE SHEET DATA
Current assets Rs m19,57724,836 78.8%   
Current liabilities Rs m14,89618,993 78.4%   
Net working cap to sales %11.920.6 57.8%  
Current ratio x1.31.3 100.5%  
Inventory Days Days9071 126.4%  
Debtors Days Days45113 40.0%  
Net fixed assets Rs m27,09734,289 79.0%   
Share capital Rs m377895 42.1%   
"Free" reserves Rs m26,81123,651 113.4%   
Net worth Rs m27,18824,546 110.8%   
Long term debt Rs m4,99315,513 32.2%   
Total assets Rs m47,77865,437 73.0%  
Interest coverage x41.71.7 2,431.5%   
Debt to equity ratio x0.20.6 29.1%  
Sales to assets ratio x0.80.4 189.8%   
Return on assets %12.64.1 309.8%  
Return on equity %21.52.9 751.4%  
Return on capital %23.66.9 342.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45315,697 123.9%   
Fx outflow Rs m6,065735 824.7%   
Net fx Rs m13,38814,962 89.5%   
CASH FLOW
From Operations Rs m8,1201,871 434.0%  
From Investments Rs m-7,5565,826 -129.7%  
From Financial Activity Rs m590-10,157 -5.8%  
Net Cashflow Rs m1,153-2,615 -44.1%  

Share Holding

Indian Promoters % 74.1 27.7 267.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 37.8 7.7%  
FIIs % 9.1 8.6 105.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 25.9 53.7%  
Shareholders   49,328 56,241 87.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS